Commercialization of Image-Guided Liver Surgery

Information

  • Research Project
  • 7387862
  • ApplicationId
    7387862
  • Core Project Number
    R44CA119502
  • Full Project Number
    4R44CA119502-02
  • Serial Number
    119502
  • FOA Number
    PA-04-63
  • Sub Project Id
  • Project Start Date
    9/29/2006 - 18 years ago
  • Project End Date
    5/31/2009 - 15 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L.
  • Budget Start Date
    6/1/2007 - 17 years ago
  • Budget End Date
    5/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/1/2007 - 17 years ago

Commercialization of Image-Guided Liver Surgery

[unreadable] DESCRIPTION (provided by applicant): For the past eight years, an image-guided liver surgery system has been developed by engineers and clinicians at several academic institutions, including Vanderbilt University and Washington University in St. Louis. In mid-2004, after initial investigations demonstrated that the system could be used in a clinical setting to more effectively treat liver cancer, Pathfinder Therapeutics, Inc. was founded as a medical device corporation to develop commercial, integrated systems for use in image-guided therapy. The primary focus of the company at this time is to take the image-guided liver surgery technology developed in the academic environment and translate it to a commercial setting where it can be specifically used to perform more efficient, accurate procedures and improve patient outcomes. Since its use in neurosurgery over ten years ago, there have always been divergent views of whether image-guided surgery has a place in a particular surgical field until the technology is proven to be effective. In order to successfully market and develop a profitable image-guided liver surgery product, we must convince surgeons that this should be the standard of care in treating several forms of liver cancer. The Phase I portion of this fast-track SBIR details the technical steps that must be completed to create a commercial-quality prototype system that can be replicated for distribution and used in an efficacy clinical trial. The clinical trial detailed in the Phase II portion will demonstrate the utility and effectiveness of image-guidance in treating liver cancer. Our trial will focus on demonstrating improvement in several factors that lead to hepatic failure, including increased residual functional liver volume following tumor resection and decreased patient time spent in the operating room. Through this investigation, we will show that image-guided liver surgery should be the standard of care for liver resection procedures. This claim will allow us to successfully commercialize image-guided liver surgery. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    963867
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:963867\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PATHFINDER THERAPEUTICS
  • Organization Department
  • Organization DUNS
    154498781
  • Organization City
    NASHVILLE
  • Organization State
    TN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    37204
  • Organization District
    UNITED STATES